OncLive TV

Mark G. Kris, MD, from Memorial Sloan-Kettering Cancer Center, discusses the administration of dacomitinib for patient with EGFR-positive lung cancer.

Scott Gettinger, MD, from the Yale School of Medicine, discusses updated results from a phase I trial that examined the novel immunotherapy BMS-936558 in patients with NSCLC and other solid tumors.

Mario E. Lacouture, MD, dermatologist, Memorial Sloan-Kettering Cancer Center, explains the challenges that need to be overcome to improve communication between oncologists and dermatologists.

José Baselga, MD, PhD, Physician-in-Chief, Memorial Sloan-Kettering Cancer Center, compares results from two trials analyzing the mTOR inhibitors temsirolimus and everolimus in breast cancer.

Erica L. Mayer, MD, MPH, assistant professor of medicine at Harvard Medical School and Dana-Farber Cancer Institute, describes studies involving tivozanib, a potent VEGF receptor tyrosine kinase inhibitor.

Gail J. Roboz, MD, associate professor of medicine, director of the Leukemia Program at the Weill Medical College of Cornell University and the New York-Presbyterian Hospital in New York City, explains research into potential improvements to the standard treatment of AML.

Mary-Ellen Taplin, MD, from the Dana-Farber Cancer Institute, discusses unique mechanism of action of enzalutamide in metastatic castration-resistant prostate cancer.

Jeffrey N. Weitzel, MD, from City of Hope, discusses the need to develop combination strategies for patients with breast cancer, in order to overcome the resistance.

Renier J. Brentjens, MD, PhD, Leukemia Service, Memorial Sloan-Kettering Cancer Center, explains the process by which his laboratory at MSKCC genetically modifies immune cells to fight cancer.

José Baselga, MD, PhD, from Memorial Sloan-Kettering Cancer Center, discusses the investigation of pan-PI3K inhibitors for patients with metastatic breast cancer.

Jason A. Konner, MD, from Memorial Sloan-Kettering Cancer Center, explains that one of the main drivers behind research into bevacizumab in ovarian cancer is to identify which patients will benefit the most from the treatment.

Mark D. Duncan, MD, from The Johns Hopkins University School of Medicine, discusses demonstrable metrics that help measure the success of a patient navigation program.

Mary Lou Woodford, from the Cancer Resource Foundation, provides guidance on staying compliant with the new patient navigation accreditation standards from the American College of Surgeons Commission on Cancer.

Debu Tripathy, MD, from the USC Norris Comprehensive Cancer Center, discusses a phase II trial that examined GRN1005 in patients with brain metastases from breast cancer.

Hope S. Rugo, MD, from the UCSF Helen Diller Family Comprehensive Cancer Center, previews the 2012 San Antonio Breast Cancer Symposium program.

William K. Oh, MD, from the Tisch Cancer Institute, discusses strategies for sequencing the new therapies that have been approved for treating castration-resistant prostate cancer.

Randall F. Holcombe, MD, from the Tisch Cancer Institute at Mount Sinai Medical Center, discusses the oral multikinase inhibitor regorafenib for patients with metastatic colorectal cancer.

Hagop M. Kantarjian, MD, from MD Anderson Cancer Center, discusses the optimal frontline therapy for patients with chronic phase chronic myelogenous leukemia.

Aleksandar Sekulic, MD, PhD, from the Mayo Clinic, Scottsdale, AZ, discusses the administration of vismodegib for the treatment and prevention of basal-cell carcinoma in patients with basal-cell nevus syndrome.

Terry P. Mamounas, MD, MPH, from Aultman Hospital Cancer Center, discusses the administration of neoadjuvant chemotherapy for patients with early-stage breast cancer.

Mark G. Kris, MD, from Memorial Sloan-Kettering Cancer Center, discusses the results of a phase III trial that studied the use of crizotinib in patients with advanced ALK-positive lung cancer.

Maurie Markman, MD, from Cancer Treatment Centers of America, discusses the AURELIA trial that examined the addition of bevacizumab to chemotherapy for women with platinum-resistant recurrent ovarian cancer.

Michael Rotkowitz, MD, from Cancer Treatment Centers of America, discusses a phase III trial that examined ipilimumab plus dacarbazine for patients with metastatic melanoma.

Sramila Aithal, MD, from Cancer Treatment Centers of America, discusses the HERceptin Adjuvant (HERA) trial that examined adjuvant therapy with trastuzumab for women with HER2-positive early breast cancer.

David R. Gandara, MD, University of California, Davis Comprehensive Cancer Center, provides his opinion on some of the most exciting research currently taking place for patients with NSCLC.

Massimo Cristofanilli, MD, from Fox Chase Cancer Center, discusses the investigation of small-molecule ALK inhibitors to treat patients with inflammatory breast cancer.

Pamela Munster, MD, from UCSF Helen Diller Family Comprehensive Cancer Center, discusses results from a phase II study that examined vorinostat in combination with tamoxifen for endocrine therapy-resistant breast cancer.

Steven I. Sherman, MD, from MD Anderson Cancer Center, discusses the clinical interest in MEK inhibitors for thyroid cancer and a broad range of other tumors that signal through the MAP kinase pathway.

Corey J. Langer, MD, from the Abramson Cancer Center, discusses the investigation of targeted therapies for patients with locally advanced non-small cell lung cancer.

Nancy L. Lewis, MD, from the Thomas Jefferson University Hospitals, discusses the phase III CORRECT trial that examined the multitargeted tyrosine kinase inhibitor regorafenib.